Researchers found no association between in vitro exposure to SSRI antidepressants and an increased risk of a child developing depression.
Ketamine's rapid action as an antidepressant is a result of increasing the activity of a small number of newborn neurons, which are part of ongoing neurogenesis in the brain.
Ketamine's antidepressant effect is a result of the enhancement of Kcnq2 potassium channels in a certain subtype of glutamate-sensitive neurons.
Researchers explore the effect psychedelics have on the brain and how they are effective at treating depression.
Researchers identify the mechanisms behind tricyclic antidepressants' ability to help relieve nerve pain.
Overall, people who used antidepressants to manage depression long-term did not have a better quality of physical or mental health than those with depression who did not use prescription medication to manage their symptoms.
A person's socioeconomic background may impact how well they respond to treatments for depression. Depressed people without a college degree had 9.8% less improvement in symptoms following treatment compared to graduates, and those who were unemployed had 6.6% less improvement than those with a steady job.
Many women experienced lingering depression throughout pregnancy and postpartum, despite using SSRI antidepressants, a new study reports.
Researchers have identified a novel biomarker for depression and antidepressant response. The biomarker can be identified and monitored through blood samples.
Hippocampal HCN channels are more highly expressed in people with major depressive disorder. Antidepressants that increase cAMP signaling interfere with TRIP8b's ability to bind to HCN channels, helping to restore cognitive ability in those with MDD.
People with untreated depression have lower levels of mitochondrial proteins. For those who responded to the SSRI antidepressants, the proteins returned to a normal level, but showed no increase in those who did not respond to medication.
A comparison of medical records reveals people who took SSRI antidepressants, specifically fluoxetine (Prozac), were less likely to die of COVID-19 than a matched control group. The findings add to a growing body of evidence that SSRIs may have beneficial effects against the worst symptoms of coronavirus.
